Compare Quest Diagnostics Inc (DGX) vs Dow Jones Industrial Average ETF (DIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Dow Jones Industrial Average ETF — how do they compare? Quest Diagnostics Inc trades at $230.98 (market cap $25.48B), while Dow Jones Industrial Average ETF trades at $515.59 (market cap $45.20B). The key difference: Dow Jones Industrial Average ETF is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Dow Jones Industrial Average ETF for 103 Days on average.
| DGX | DIA | |
|---|---|---|
Market Cap | $25.48B | $45.20B |
Volume | 941,866 | 4,095,368 |
Sector | Health | — |
52-Week High | $247.45 | $542.79 |
52-Week Low | $173.49 | $451.37 |
Typical Hold Time | 56 Days | 103 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
DIA trades at $513.34, showing modest 0.45% daily gains amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent dividend distributions provide income appeal, but key valuation metrics are unavailable for comprehensive fundamental assessment. Market sentiment reflects broader equity concerns as highlighted in recent financial coverage.
The outlook remains cautious given technical weakness and market volatility. Dividend payments offer income stability, but the absence of fundamental metrics limits valuation clarity. Key risks include broader market pressures and economic uncertainty, requiring careful monitoring of Dow Jones component performance for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →
